Drug Combination Details
| General Information of the Combination (ID: C96810) | |||||
|---|---|---|---|---|---|
| Name | Curcumin NP Info | + | HSV-TK/GCV Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Melanoma
[ICD-11: 2C30]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | Cx32 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | GJA1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | B16 | CVCL_F936 | Mouse melanoma | Mus musculus | ||
| In-vivo Model | A total of 2*105 B16 cells in a final volume of 100L was injected into the right flanks of each C57BL/6J mouse. | |||||
| Experimental
Result(s) |
Curcumin could enhance the killing effect and the bystander effect of HSV-TK/GCV in treating melanoma, which might be mediated by improved gap junction. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Curcumin plays a synergistic role in combination with HSV-TK/GCV in inhibiting growth of murine B16 melanoma cells and melanoma xenografts. PeerJ. 2019 Sep 20;7:e7760. | |||
